{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:55:39Z","timestamp":1726106139662},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T00:00:00Z","timestamp":1142467200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non -treated control patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply<jats:italic>per se<\/jats:italic>that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-244x-6-11","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T12:47:27Z","timestamp":1144327647000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre"],"prefix":"10.1186","volume":"6","author":[{"given":"Ilaria","family":"Tarricone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Casoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Ferrari","family":"Gozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Menchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjola","family":"Ujkaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pastorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,16]]},"reference":[{"key":"140_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"JM Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Genl Psychiatry. 2003, 60: 553-564. 10.1001\/archpsyc.60.6.553.","journal-title":"Arch Genl Psychiatry"},{"key":"140_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2004.11.002","volume":"20","author":"JM Davis","year":"2005","unstructured":"Davis JM, Chen N: Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry. 2005, 20: 7-14. 10.1016\/j.eurpsy.2004.11.002.","journal-title":"Eur Psychiatry"},{"key":"140_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27: 596-601.","journal-title":"Diabetes Care"},{"key":"140_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","volume":"70","author":"JM Meyer","year":"2004","unstructured":"Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004, 70: 1-17. 10.1016\/j.schres.2004.01.014.","journal-title":"Schizophr Res"},{"key":"140_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00004714-200108000-00003","volume":"21","author":"JM Meyer","year":"2001","unstructured":"Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001, 21: 369-74. 10.1097\/00004714-200108000-00003.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","volume":"64","author":"K Melkersson","year":"2004","unstructured":"Melkersson K, Dahl M-L: Adverse metabolic effects associated with atypical antipsychotics. Drugs. 2004, 64: 701-23. 10.2165\/00003495-200464070-00003.","journal-title":"Drugs"},{"issue":"Suppl 7","key":"140_CR7","first-page":"4","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH: Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004, 65 (Suppl 7): 4-18.","journal-title":"J Clin Psychiatry"},{"issue":"47","key":"140_CR8","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1192\/bjp.184.47.s112","volume":"184","author":"Expert group 'Schizophrenia and Diabetes 2003'","year":"2004","unstructured":"Expert group 'Schizophrenia and Diabetes 2003': Expert Consensus Meeting, Dublin 3\u20134 october 2003: consensus summary. Br J Psychiatry. 2004, 184 (47): S112-S114. 10.1192\/bjp.184.47.s112.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"140_CR9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/j.1326-5377.2004.tb06443.x","volume":"181","author":"TJ Lambert","year":"2004","unstructured":"Lambert TJ, Chapman LH, Consensus Working Group: Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust. 2004, 181 (10): 544-8.","journal-title":"Med J Aust"},{"key":"140_CR10","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington DC: APA, 4","edition":"4"},{"issue":"6","key":"140_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","volume":"157","author":"DC Henderson","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. Am J Psychiatry. 2000, 157 (6): 975-981. 10.1176\/appi.ajp.157.6.975.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 27","key":"140_CR12","first-page":"15","volume":"62","author":"DW Haupt","year":"2001","unstructured":"Haupt DW, Newcomer JW: Hyperglycemia and antipsychotic medications. Journal of Clinical Psychiatry. 2001, 62 (Suppl 27): 15-26.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"140_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/10401230109148955","volume":"13","author":"DS Dwyer","year":"2001","unstructured":"Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM: Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Annals of Clinical Psychiatry. 2001, 13 (2): 103-13. 10.1023\/A:1016671725396.","journal-title":"Annals of Clinical Psychiatry"},{"key":"140_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1606.","journal-title":"Diabetes"},{"key":"140_CR15","first-page":"3143","volume":"106","author":"National Cholesterol Education Program Expert Panel: Third report of the National and Cholesterol Education Program (NCEP)","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel: Third report of the National and Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III) final report. 2002, 106: 3143-3421.","journal-title":"(Adult Treatment Panel III) final report"},{"key":"140_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"K Alberti","year":"1998","unstructured":"Alberti K, Zimmet P, Consultation W: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med. 1998, 15: 539-53. 10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.","journal-title":"Diabetic Med"},{"key":"140_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/bmj.325.7358.243","volume":"325","author":"CE Koro","year":"2002","unstructured":"Koro CE, Fedder DO, Gilbert J, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002, 325: 325-243. 10.1136\/bmj.325.7358.243.","journal-title":"BMJ"},{"issue":"11","key":"140_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","volume":"59","author":"CE Koro","year":"2002","unstructured":"Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002, 59 (11): 1021-6. 10.1001\/archpsyc.59.11.1021.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","volume":"56","author":"JB Buse","year":"2003","unstructured":"Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiology. 2003, 56: 164-170. 10.1016\/S0895-4356(02)00588-7.","journal-title":"J Clin Epidemiology"},{"key":"140_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","volume":"159","author":"MJ Sernyak","year":"2002","unstructured":"Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002, 159: 561-566. 10.1176\/appi.ajp.159.4.561.","journal-title":"Am J Psychiatry"},{"key":"140_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.4088\/JCP.v63n1010","volume":"63","author":"FD Gianfrancesco","year":"2002","unstructured":"Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002, 63: 920-930.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"140_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","volume":"55","author":"L Citrome","year":"2004","unstructured":"Citrome L, Jaffe A, Allingham B, Robinson J: Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004, 55 (9): 1006-1013. 10.1176\/appi.ps.55.9.1006.","journal-title":"Psychiatr Serv"},{"key":"140_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4088\/JCP.v65n0417","volume":"65","author":"N Almeras","year":"2004","unstructured":"Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH: Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004, 65: 557-564.","journal-title":"J Clin Psychiatry"},{"key":"140_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002, 59: 337-345. 10.1001\/archpsyc.59.4.337.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"140_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S1461145705005110","volume":"8","author":"RC Smith","year":"2005","unstructured":"Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A: Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol. 2005, 8 (2): 183-94. 10.1017\/S1461145705005110.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"140_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4088\/JCP.v62n0404","volume":"62","author":"BR Basson","year":"2001","unstructured":"Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry. 2001, 62 (4): 231-238.","journal-title":"J Clin Psychiatry"},{"key":"140_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4088\/JCP.v62n0204","volume":"62","author":"BJ Kinon","year":"2001","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001, 62: 92-100.","journal-title":"J Clin Psychiatry"},{"key":"140_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","volume":"160","author":"JP Lindenmayer","year":"2003","unstructured":"Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003, 160: 290-296. 10.1176\/appi.ajp.160.2.290.","journal-title":"Am J Psychiatry"},{"key":"140_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1176\/appi.ajp.161.2.361","volume":"161","author":"OD Howes","year":"2004","unstructured":"Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS: A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry. 2004, 161: 361-363. 10.1176\/appi.ajp.161.2.361.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"140_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","volume":"2","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005, 2 (1): 19-28. 10.1001\/archpsyc.62.1.19.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"140_CR31","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S0149-2918(03)80073-5","volume":"25","author":"F Gianfrancesco","year":"2003","unstructured":"Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D: Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther. 2003, 25 (4): 1150-71. 10.1016\/S0149-2918(03)80073-5.","journal-title":"Clin Ther"},{"key":"140_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","volume":"5","author":"M Hummer","year":"1995","unstructured":"Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW: Weight gain induced by Clozapine. Eur Neuropsychopharmacol. 1995, 5: 437-440. 10.1016\/0924-977X(95)00012-E.","journal-title":"Eur Neuropsychopharmacol"},{"key":"140_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3109\/00048679809113128","volume":"32","author":"D Briffa","year":"1998","unstructured":"Briffa D, Meehan T: Weight changes during clozapine treatment. Aust N Z J Psychiatry. 1998, 32: 718-721.","journal-title":"Aust N Z J Psychiatry"},{"key":"140_CR34","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4088\/JCP.v64n0516","volume":"64","author":"M Atmaca","year":"2003","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypycal antipsychotics. J Clin Psychiatry. 2003, 64: 598-604.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"140_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/oxfordjournals.schbul.a007074","volume":"30","author":"NH Covell","year":"2004","unstructured":"Covell NH, Weissman EM, Essock SM: Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004, 30 (2): 229-40.","journal-title":"Schizophr Bull"},{"issue":"11","key":"140_CR36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al: Antipsychotic-induced weight gain; a comprehensive research synthesis. Am J Psychiatry. 1999, 156 (11): 1686-1696.","journal-title":"Am J Psychiatry"},{"key":"140_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eurpsy.2003.06.002","volume":"18","author":"G Garyfallos","year":"2003","unstructured":"Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, Giouzepas J, Fokas K: Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry. 2003, 18: 320-321. 10.1016\/j.eurpsy.2003.06.002.","journal-title":"Eur Psychiatry"},{"key":"140_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-244X-5-3","volume":"5","author":"H Ascher-Svanum","year":"2005","unstructured":"Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ: Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005, 5: 3-10.1186\/1471-244X-5-3.","journal-title":"BMC Psychiatry"},{"issue":"12","key":"140_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO: Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-23. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"issue":"13","key":"140_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1503\/cmaj.1041064","volume":"172","author":"DM Gardner","year":"2005","unstructured":"Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: a critical overview. CMAJ. 2005, 172 (13): 1703-11.","journal-title":"CMAJ"},{"key":"140_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","volume":"101","author":"KR Fontaine","year":"2001","unstructured":"Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001, 101: 277-88. 10.1016\/S0165-1781(01)00234-7.","journal-title":"Psychiatry Res"},{"issue":"4","key":"140_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1176\/appi.ajp.160.4.677","volume":"160","author":"GP Reynolds","year":"2003","unstructured":"Reynolds GP, Zhang Z, Zhang X: Polymorphism of the promoter region of the Serotonin 5-HT2c receptor gene and clozapine \u2013 induced weight gain. Am J Psychiatry. 2003, 160 (4): 677-79. 10.1176\/appi.ajp.160.4.677.","journal-title":"Am J Psychiatry"},{"key":"140_CR43","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/archpsyc.58.12.1172","volume":"58","author":"BC Lund","year":"2001","unstructured":"Lund BC, Perry PJ, Brooks JM, Arndt S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Archives of General Psychiatry. 2001, 58: 1172-1176. 10.1001\/archpsyc.58.12.1172.","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"140_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2337\/diacare.25.5.829","volume":"25","author":"DW Dunstan","year":"2002","unstructured":"Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002, 25 (5): 829-34.","journal-title":"Diabetes Care"},{"issue":"10","key":"140_CR45","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.2337\/diacare.27.10.2444","volume":"27","author":"ES Ford","year":"2004","unstructured":"Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the Metabolic Syndrome Among U.S. Adults. Diabetes Care. 2004, 27 (10): 2444-2449.","journal-title":"Diabetes Care"},{"issue":"6","key":"140_CR46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/070674370104600610","volume":"46","author":"S Coodin","year":"2001","unstructured":"Coodin S: Body mass index in persons with schizophrenia. Can J Psychiatry. 2001, 46 (6): 549-55.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"140_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","volume":"55","author":"P Homel","year":"2002","unstructured":"Homel P, Casey D, Allison DB: Changes in body mass index for individuals with and without schizophrenia, 1987\u20131996. Schizophr Res. 2002, 55 (3): 277-284. 10.1016\/S0920-9964(01)00256-0.","journal-title":"Schizophr Res"},{"issue":"5","key":"140_CR48","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1600-0447.2003.00218.x","volume":"108","author":"G Faulkner","year":"2003","unstructured":"Faulkner G, Soundy AA, Lloyd K: Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003, 108 (5): 324-32. 10.1034\/j.1600-0447.2003.00218.x.","journal-title":"Acta Psychiatr Scand"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-6-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T23:13:20Z","timestamp":1683414800000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-6-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,16]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-6-11","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,16]]},"assertion":[{"value":"12 August 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}